Morgan Stanley Maintains a Buy Rating on Metlife (MET)
Morgan Stanley analyst Nigel Dally maintained a Buy rating on Metlife (MET) on February 6 and set a price target of $60.00. The company’s shares closed last Monday at $51.58, close to its 52-week high of $52.76.
According to TipRanks.com, Dally is a 4-star analyst with an average return of 11.2% and a 68.2% success rate. Dally covers the Financial sector, focusing on stocks such as AXA Equitable Holdings, Brighthouse Financial, and Ameriprise Financial.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Metlife with a $57.50 average price target, which is an 11.6% upside from current levels. In a report issued on February 3, Credit Suisse also maintained a Buy rating on the stock with a $60.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $52.76 and a one-year low of $41.41. Currently, Metlife has an average volume of 5.13M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MetLife, Inc. provides insurance and financial services to individual and institutional customers. It offers life insurance, annuities, automobile and homeowner’s insurance and retail banking services to individuals as well as group insurance, reinsurance and retirement and savings products and services. The company operates through the following segments: U.